An observational study in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 50 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-14.
Sponsored by Novo Nordisk A/S · Observational
The purpose of this study is to collect information on how Ryzodeg® works in real-world patients.
Participants will get Ryzodeg® as prescribed to by their doctor. The study will last for about 5-8 months. Participants will be asked questions about their health and their diabetes treatment as part of their normal doctor's appointment
9,362 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,317 are open to participants now.
This study's enrollment of 887 is above the median of 300 across 1,588 observational studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,370 studies on the registry; 101 are open to participants now.
Of its 198 completed or terminated interventional studies of FDA-regulated products, 94 (47%) have results posted.
Counted across the registry records on this site, refreshed daily.
Real-world adult population with type 2 diabetes in China.
Exclusion Criteria:
Ryzodec as per local clinical practise
Drug: Ryzodeg®
Patients will be treated with commercially available Ryzodeg® in a prefilled device (FlexTouch®) or in a penfill according to the label and routine clinical practice at the discretion of the treating physician
Change in Glycosylated Haemoglobin (HbA1c)
Percentage point
Time frame: From baseline (week 0) to end of study (week 20 to 32)
HbA1c less than 7 percent (Yes/No)
Percentage of patients
Time frame: At the end of study (week 20 to 32)
HbA1c less than 7 percent without any hypoglycaemic episodes during 4 weeks prior to end of study (Yes/No)
Percentage of patients
Time frame: At the end of study (week 20 to 32) Hypoglycaemic episodes occurring within 4 weeks prior to end of study (week 20 to 32).
Change in Fasting Plasma Glucose (FPG)
mmol/L
Time frame: From baseline (week 0) to end of study (week 20 to 32)
Change in insulin dose (total, basal, prandial)
units/day
Time frame: From baseline (week 0) to end of study (week 20 to 32)
Change in body weight
Kg
Time frame: From baseline (week 0) to end of study (week 20 to 32)
Patient preference compared to previous treatment
Percentage of patients who prefer to continue treatment with Ryzodeg® over previous treatment. Assessed by questionnaire
Time frame: At baseline and end of study (week 20 to 32)
Treatment satisfaction questionnaire (Diabetes Treatment Satisfaction Questionnaire (DTSQ))
Score based on items 1, 4, 5, 6, 7 and 8. Range 0-36, where higher score means greater satisfaction (better outcome)
Time frame: At baseline and end of study (week 20 to 32)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novo Nordisk A/S